On October 18th, 2019, the FDA approved Amzeeq, otherwise known as FMX101 for the Israel based pharmaceutical company, Foamix. Amzeeq happens to be the first and only topical monocyline treatment to be used on acne patients. In anticipation of approval for this new product, shares of FOMX rallied from $2.53 per share on 10/08/2019 all the way up to highs around...
Biotech has had a hard time of it lately due to both political risks related to the election and litigation risks from the opioid epidemic. All of this, of course, on top of broad market weakness due to the China trade war. However, biotech earnings are better than most sectors this season, so the bear market likely won't continue forever. I've drawn a trend line...
I found a strong sector because there are strongly proves the pharmaceuticals helps to improve the quality of life and increases life expectancy
the pharmaceuticals are performing well so the market makers are currently buying on this sector, my principal list on this sector are AMGEN, PFIZER and BRISTOL MYERS, i'm waiting to break levels to buy
Assertio therapeutics is slated to get an FDA ruling on its new drug application for cosyntropin depot by October 19. If the FDA approves the drug, the stock could move up significantly. Assertio has an 8.9/10 Equity StarMine Summary Score and is rated extremely undervalued by S&P Capital IQ. Despite relatively good earnings last quarter, the stock price is down...
Fundamental analysis In one of the first state opioid cases, an Oklahoma judge ruled against Johnson & Johnson, awarding the state $572 million, well below the over $17 billion the state was seeking in damages. Meaning... out of the 17 billion, they lost only 3.36%, and they expect to appeal the case, probably lowering this amount. Technical analysis On a...
#NIFTYPHARMA 500 point rally possible?
#TORNTPHARM Cup and Handle Breakout @anish_sharmaaa View negated below 1595...
BUY signal at 20.98 $ Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. If you want to see more history of this strategy, I will able to show you if you request me. ATTENTION this strategy may...
SELL – GLAXOSMITHKLINE (GSK) GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. Fundamentals...
Possible retracement to 200-Day MA ($3.00). Series of higher lows on the 2-month chart!
It's been a banner quarter for large-cap pharmaceutical companies. We've had earnings beats and guidance upgrades from GlaxoSmithKline, Biogen, Bristol-Myers Squibb, Merck, Celgene, and Procter & Gamble. More earnings beats may be coming, with Amgen reporting today after market and Amarin tomorrow. In my opinion, the whole sector is set to surge, and the leveraged...
Amgen is attempting a breakout above its one-month downward trend line this morning. I will wait to enter until I see a change in volume. Currently there's bearish divergence on the volume profile, which suggests that this may correct downward before confirming the breakout. Amgen reports earnings tomorrow, and has a positive earnings surprise prediction from...
Biogen has formed an ascending triangle. With strong earnings and a guidance upgrade, the catalysts favor upward breakout. However, certain aspects of Biogen's business are struggling and face increasing competition, so the stock could also fall. I will play oscillations within the triangle by buying and selling crossovers of the green line, with stop losses in...
Zynerba Pharmaceuticals has been surging since it got added to the Russell 2000 and 3000 indices. It is in an upward channel, just broke trendline resistance, and looks strong on the indicators, including high buying volume. It will meet short-term resistance around 16.47. Look for a break above that level on volume.
BIIB is up this morning on an extremely strong earnings beat and a guidance upgrade. BIIB has an upside gap to fill, with some clearance on the volume profile. That should make it fairly easy for BIIB to keep moving upward to 280 once it breaks decisively above 245.35 resistance.
Generic drug maker Amneal has been slowly melting down since 2015, falling from $50 per share to today's closing price of $3.44. Amneal makes money, though it missed estimates last quarter by about $0.04 per share. S&P Capital IQ rates it an undervalued, high quality, and financially healthy company, but I think that overstates the case. In my opinion this...
Merck ended the day near the bottom of its parallel channel, right above a high-volume support node at 8.19 and a trend line that's parallel with channel bottom. After hours, the price has moved below both the support and the trend line, but in my experience, after hours moves don't necessarily mean much. The real test will be tomorrow after market open. If the...